Elevated Serum IgA and IgA Nephropathy
Elevated serum IgA levels alone are NOT diagnostic of IgA nephropathy and should not be used to make or exclude the diagnosis—kidney biopsy remains the only definitive diagnostic test. 1
Critical Diagnostic Principle
The 2025 KDIGO guidelines explicitly state that there are no validated diagnostic serum or urine biomarkers for IgAN, including serum IgA levels 1. This represents the highest-quality, most recent guideline evidence available and fundamentally shapes clinical decision-making.
Clinical Significance of Elevated Serum IgA
Limited Diagnostic Value
While approximately 30-50% of patients with IgA nephropathy have elevated serum IgA levels 2, 3, this finding has several critical limitations:
- Poor sensitivity: Many patients with biopsy-proven IgAN have normal serum IgA levels
- Poor specificity: Elevated serum IgA occurs in numerous other conditions (liver disease, infections, inflammatory bowel disease, autoimmune disorders)
- Cannot replace biopsy: The diagnosis of IgAN requires demonstration of IgA-dominant immune deposits in the glomerular mesangium on kidney biopsy 4
Potential Supportive Role
Older research suggests that combining elevated serum IgA (>315 mg/dL) with other clinical markers—microscopic hematuria, persistent proteinuria (>0.3 g/day), and serum IgA/C3 ratio >3.01—may support clinical suspicion 2. However, this combination cannot substitute for biopsy confirmation and is not endorsed by current guidelines.
When to Pursue Kidney Biopsy
The 2025 KDIGO guidelines recommend a more liberal biopsy policy 1:
Proceed with kidney biopsy in all adults with:
- Proteinuria ≥0.5 g/day (or equivalent) AND
- Clinical suspicion of IgAN (typically hematuria with or without proteinuria)
Common Clinical Presentations Warranting Biopsy:
- Persistent microscopic hematuria with proteinuria
- Episodic gross hematuria (especially synpharyngitic—occurring with upper respiratory infections)
- Unexplained proteinuria with hematuria
- Declining kidney function with active urinary sediment
Pathophysiologic Link
The actual pathogenic mechanism involves galactose-deficient IgA1 (Gd-IgA1) forming immune complexes that deposit in the glomerular mesangium 4, 5. Standard serum IgA measurements do not distinguish between normal IgA and pathogenic Gd-IgA1, explaining why total serum IgA levels lack diagnostic utility.
Research has shown that polymeric IgA immune complexes (not simply elevated total IgA) correlate better with disease activity 6, but these specialized assays are not clinically validated or routinely available.
Critical Pitfalls to Avoid
- Never delay biopsy based on normal serum IgA levels in a patient with appropriate clinical features
- Never diagnose IgAN based on elevated serum IgA alone without biopsy confirmation
- Always exclude secondary causes of IgA deposition (IgA vasculitis, cirrhosis, inflammatory bowel disease, infections) even when biopsy shows IgA-dominant deposits 4
- Do not use serum IgA for disease monitoring or treatment response—proteinuria and eGFR are the validated biomarkers 1
Post-Diagnosis Management Framework
Once IgAN is biopsy-confirmed, management focuses on:
- Risk stratification using the International IgAN Prediction Tool and MEST-C histologic scoring 1
- Treatment goals: Proteinuria <0.5 g/day (ideally <0.3 g/day), blood pressure <120/70 mmHg 1
- Dual therapeutic approach: Target both immune-mediated injury (targeted-release budesonide, complement inhibitors) and manage CKD consequences (RAS inhibition, SGLT2 inhibitors) 4
The bottom line: Serum IgA elevation may raise clinical suspicion but provides no diagnostic certainty. Kidney biopsy remains mandatory for diagnosis, and subsequent management should be guided by validated prognostic tools rather than serum IgA levels.